Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Sold by Homestead Advisers Corp

Homestead Advisers Corp trimmed its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 40.1% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 12,250 shares of the company's stock after selling 8,200 shares during the quarter. Homestead Advisers Corp's holdings in Medpace were worth $4,070,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in MEDP. R Squared Ltd bought a new position in shares of Medpace during the 4th quarter worth $30,000. SBI Securities Co. Ltd. acquired a new stake in Medpace in the 4th quarter worth approximately $31,000. Stone House Investment Management LLC purchased a new stake in Medpace during the 3rd quarter worth approximately $33,000. Jones Financial Companies Lllp increased its stake in Medpace by 2,750.0% during the 4th quarter. Jones Financial Companies Lllp now owns 114 shares of the company's stock valued at $38,000 after purchasing an additional 110 shares in the last quarter. Finally, Lindbrook Capital LLC raised its holdings in shares of Medpace by 27.6% in the fourth quarter. Lindbrook Capital LLC now owns 134 shares of the company's stock worth $45,000 after buying an additional 29 shares during the last quarter. 77.98% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

MEDP has been the topic of several research reports. Leerink Partnrs raised Medpace to a "hold" rating in a research report on Monday, March 24th. Leerink Partners started coverage on Medpace in a research note on Monday, March 24th. They issued a "market perform" rating and a $330.00 price objective for the company. Finally, Robert W. Baird upped their target price on Medpace from $354.00 to $362.00 and gave the company a "neutral" rating in a research report on Monday, January 27th. Nine investment analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. According to data from MarketBeat, Medpace has an average rating of "Hold" and a consensus target price of $376.30.

Remove Ads

Medpace Stock Down 5.4 %

Shares of NASDAQ MEDP traded down $16.83 during midday trading on Monday, reaching $295.53. 269,351 shares of the stock were exchanged, compared to its average volume of 298,679. The firm has a 50-day simple moving average of $335.90 and a two-hundred day simple moving average of $339.18. Medpace Holdings, Inc. has a twelve month low of $289.21 and a twelve month high of $459.77. The firm has a market cap of $9.00 billion, a price-to-earnings ratio of 23.40, a PEG ratio of 3.81 and a beta of 1.47.

Medpace (NASDAQ:MEDP - Get Free Report) last announced its quarterly earnings results on Monday, February 10th. The company reported $3.67 earnings per share for the quarter, beating the consensus estimate of $2.96 by $0.71. Medpace had a return on equity of 51.48% and a net margin of 19.17%. Research analysts expect that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.